Pharmafile Logo

MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke

January 7, 2026 | Intelligent Commercialization 

The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what AI-powered audience intelligence means for life sciences organizations heading into 2026.

Evoke-Podcast

How AI and LLMs are shaping audience intelligence in life sciences

In the episode, they examine how life sciences companies are approaching AI and Large Language Models (LLMs), the challenges created by gaps in data sets, and why context and real behavior matter when predicting how healthcare professionals and patients engage.

Why real behavior and high-quality data are critical for predictive accuracy

The discussion focuses on several key themes, including: 

  • The limitations of narrow or closed data inputs and how they restrict prediction accuracy 
  • The importance of understanding real behavior beyond a single organization’s data 
  • Why high-quality, holistic data sets are essential to improving LLM performance 
  • The role of subject matter experts in providing context that general-purpose models currently lack 
  • How data quality directly influences the usefulness and reliability of AI tools 

Together, Jamie and Iris highlight how more precise, behavior-informed audience intelligence can support better decision-making as AI becomes increasingly central to life sciences marketing and engagement. 

Listen to the full MM+M Podcast episode: “Beyond the algorithm: What AI-powered audience intelligence really means in 2026.”

Intelligent Commercialization™ in action

This perspective is core to how Inizio delivers Intelligent Commercialization™ – our unified, expert-driven approach that connects proprietary data, technology, and AI to unlock measurable impact across the product lifecycle. Platforms such as Cognitev™ and Predictev™ (referenced in the discussion) translate over 35M hours of real-world behavior into actionable intelligence, enabling clients to anticipate shifts, optimize engagement, and make smarter decisions with confidence.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Healthcare in the age of AI: How will artificial intelligence impact future decision-making?

Authored by: Constanza Salas, Jhon Galindo and Rachel Howard

Therapy Watch launches new tracker covering Postpartum Depression

The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

Man vs microbe: the fight against antimicrobial resistance

How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.

Research Partnership Senior Director Andrew Stokes appointed new role as Chief Commercial Officer

With over 20 years' experience in the industry, Research Partnership Senior Director and market research veteran Andrew Stokes has been appointed Chief Commercial Officer.

Case study: How we enhanced the power of a global ATU using our advanced analytics solution, Equity AI

Find out how we provided a more holistic understanding of brand equity and a forward indication of potential market share using our advanced analytics solution, Equity AI.

Article: Creating truly effective communications – the impact of high speed, high octane messaging

In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.

Research Partnership makes two senior appointments to bolster its US and MedTech operations

Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.